Device tax spurs Hill-Rom to lay off 200 | Wall Street Beat Wall Street Beat

Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.

"The company is making these changes to help offset pressures from challenging macroeconomic conditions, regulatory and reimbursement pressures, and the new medical device tax," according to a regulatory filing.

Batesville, Ind.-based Hill-Rom also said it’s taking a $10 million to $13 million hit this year on tangible and intangible impairments, meaning a total charge of $19 million to $22 million for 2012.

Hill-Rom joins Stryker (NYSE:SYK) and Zimmer (NYSE:ZMH) in linking layoffs with the med-tech tax, a 2.3% levy on all U.S. sales of medical devices slated to begin next year. Earlier this month, Zimmer said it plans to offset the entire burden posed by the tax in 2013, in part by laying off about 170 workers. Stryker said late last year that it will cut 5% of its workforce due to the tax, and industry lobby AdvaMed has estimated that the levy will cost the med-tech sector about 11% of its jobs.

 AngioDynamics drops $5M on Microsulis
AngioDynamics (NSDQ:ANGO) said it paid $5 million to acquire a 14.3% stake in microwave ablation developer Microsulis Medical Ltd., in return for exclusive overseas distribution rights to the Accu2i pMTA microwave ablation system and an exclusive option to "buy" Microsulis. Read more

 Kips Bay switches NASDAQ markets

The NASDAQ stock exchange granted Kips Bay Medical‘s (NSDQ:KIPS) request to move from its Global Market to the NASDAQ Capital Market "to take advantage of the Capital Market’s lower listing requirements." Read more

 Luna Innovations, Intuitive Surgical extend pact
Luna Innovations NSDQ:LUNA) and Intuitive Surgical (NSDQ:ISRG) extended a development deal through 2012 to integrate Luna’s shape and position sensing technology into Intuitive’s surgery robots. Read more

 Asahi Kasei begins $2B bid for Zoll

Asahi Kasei (TYO:3407) began its $2.2 billion tender offer for Zoll Medical (NSDQ:ZOLL) at $93 per share. Read more

 CRO Cetero files for bankruptcy after FDA probe
Contract research organization Cetero Research filed for bankruptcy after an FDA probe into allegedly falsified data caused the company’s "liquidity position to become severely constrained" and some lenders declared default due to the "apparent violation of applicable health laws and regulations." Read more

 NASDAQ warns NeuroMetrix

NeuroMetrix (NSDQ:NURO) said the NASDAQ stock exchange warned it of a possible de-listing after its stock price moved below the exchange’s $1-per-share minimum price requirement. Read more

 Report: Six players dominate the EMR market

A sextet of major players – Cerner Cerner (NSDQ:CERN), McKesson McKesson (NYSE:MCK), Siemens Siemens (NYSE:SI), GE Healthcare GE (NYSE:GE), Epic and Allscripts (NSDQ:MDRX) – dominates the market for electronic medical records, according to Kalorama Information. Read more

 Intuitive Surgical, GE, Hitachi, Philips win federal contracts

Intuitive Surgical (NSDQ:ISRG), GE (NYSE:GE), Hitachi (NYSE:HIT) and Philips (NYSE:PHG) all won contracts with the U.S. Defense Dept. 

 Funding Roundup

 Analysts’ ups and downs

  • Allergan (NYSE:AGN): Citigroup increases price target from $94 to $110, maintains "buy" rating.
  • Cardiovascular Systems (NSDQ:CSII): Benchmark Co. initiates coverage with "speculative buy" rating, $15 price target.
  • Edwards Lifesciences (NYSE:EW): JP Morgan maintains "neutral" rating; Citi maintains "buy" rating, $84 price target.
  • Insulet (NSDQ:PODD): Piper Jaffray initiates with "neutral" rating, $21 price target.
  • McKesson (NYSE:MCK): Goldman Sachs raises estimates through 2014, maintains "buy" rating.
  • Opko (NYSE:OPK): Ladenburg Thalmann maintains "buy" rating, $8.50 price target.
  • Smith & Nephew (FTSE:SN): Investec downgrades from "buy" to hold, cuts price target from £6.63 to £6.60.
  • St. Jude Medical (NYSE:STJ): Credit Suisse raises price target from $44 to $49, maintains "outperform" rating.
  • Synergetics (NSDQ:SURG): Wunderlich Securities maintains "buy" rating, $8 target price.
  • Tornier (NSDQ:TRNX): Benchmark Co. initiates coverage at "speculative buy", $31 price target.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply